Twist Bioscience Beheer

Beheer criteriumcontroles 2/4

De CEO Twist Bioscience is Emily Leproust, benoemd in Apr2013, heeft een ambtstermijn van 11.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.00M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.47% van de aandelen van het bedrijf, ter waarde € 12.41M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 8 jaar.

Belangrijke informatie

Emily Leproust

Algemeen directeur

US$8.0m

Totale compensatie

Percentage CEO-salaris	8.6%
Dienstverband CEO	11.6yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Emily Leproust's beloning veranderd ten opzichte van Twist Bioscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$209m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	n/a	n/a	-US$192m
Dec 31 2023	n/a	n/a	-US$206m
Sep 30 2023	US$8m	US$685k	-US$205m
Jun 30 2023	n/a	n/a	-US$209m
Mar 31 2023	n/a	n/a	-US$213m
Dec 31 2022	n/a	n/a	-US$214m
Sep 30 2022	US$6m	US$665k	-US$218m
Jun 30 2022	n/a	n/a	-US$208m
Mar 31 2022	n/a	n/a	-US$188m
Dec 31 2021	n/a	n/a	-US$165m
Sep 30 2021	US$1m	US$590k	-US$152m
Jun 30 2021	n/a	n/a	-US$135m
Mar 31 2021	n/a	n/a	-US$123m
Dec 31 2020	n/a	n/a	-US$117m
Sep 30 2020	US$7m	US$519k	-US$140m
Jun 30 2020	n/a	n/a	-US$147m
Mar 31 2020	n/a	n/a	-US$147m
Dec 31 2019	n/a	n/a	-US$141m
Sep 30 2019	US$8m	US$477k	-US$108m
Jun 30 2019	n/a	n/a	-US$96m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	n/a	n/a	-US$77m
Sep 30 2018	US$525k	US$362k	-US$71m

Compensatie versus markt: De totale vergoeding ($USD 8.00M ) Emily } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.92M ).

Compensatie versus inkomsten: De vergoeding van Emily is gestegen terwijl het bedrijf verliesgevend is.

CEO

Emily Leproust (51 yo)

11.6yrs

Tenure

US$7,998,637

Compensatie

Dr. Emily Marine Leproust, Ph.D. serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at GeneDx Holdings Corp. (formerly known as Sema4 Ho...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Emily Leproust	Co-Founder	11.6yrs	US$8.00m	0.47% € 12.4m
Patrick Finn	President & COO	2.1yrs	US$5.23m	0.13% € 3.4m
Paula Green	Senior Vice President of Human Resources	8.7yrs	US$2.49m	0.060% € 1.6m
William Banyai	Senior VP of Advanced Development	4.8yrs	US$2.82m	0.44% € 11.4m
Adam Laponis	Chief Financial Officer	less than a year	geen gegevens	0.012% € 306.8k
Robert Werner	VP & Chief Accounting Officer	1.5yrs	geen gegevens	0.016% € 411.7k
Siyuan Chen	Chief Technology Officer	3.8yrs	geen gegevens	geen gegevens
Michael Fero	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Dennis Cho	Senior VP	3.2yrs	US$1.96m	0.067% € 1.8m
Nicole Moreno	Senior Vice President of Sales & Support	no data	geen gegevens	geen gegevens
Angela Bitting	Chief ESG Officer & Senior VP of Corporate Affairs	3.8yrs	geen gegevens	geen gegevens
Mark Buck	Senior Vice President of Operations	1.1yrs	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0ME wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Emily Leproust	Co-Founder	11.6yrs	US$8.00m	0.47% € 12.4m
William Banyai	Senior VP of Advanced Development	11.6yrs	US$2.82m	0.44% € 11.4m
Keith Crandell	Independent Director	11.1yrs	US$272.49k	0.16% € 4.2m
Robert Chess	Lead Independent Director	10.3yrs	US$303.98k	0.11% € 2.8m
Nelson Chan	Independent Director	5.5yrs	US$284.99k	0.030% € 791.3k
Robert Ragusa	Independent Director	8yrs	US$271.34k	0.023% € 602.3k
Jan Johannessen	Independent Director	6.1yrs	US$284.99k	0.020% € 514.5k
Melissa Starovasnik	Independent Director	3.3yrs	US$276.61k	0.018% € 482.1k
Xiaoying Mai	Independent Director	6.3yrs	US$269.99k	0.043% € 1.1m

8.0yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0ME wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).

Twist Bioscience Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Co-Founder recently sold €596k worth of stock

Twist Bioscience Corporation Appoints Mike Fero as Chief Information Officer

Co-Founder recently sold €532k worth of stock

Twist Bioscience Corporation, Annual General Meeting, Feb 06, 2024

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

Twist Bioscience Corporation Appoints Mark Buck as Senior Vice President, Operations

Recent updates

Twist Bioscience Corporation Provides Financial Guidance for the First Quarter and Full Fiscal Year of 2025

Co-Founder recently sold €596k worth of stock

Twist Bioscience Launches Flexprep Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics

Twist Bioscience Corporation to Report Q4, 2024 Results on Nov 18, 2024

Twist Bioscience Corporation Appoints Mike Fero as Chief Information Officer

Co-Founder recently sold €532k worth of stock

Twist Bioscience Corporation Expands Gene Offering with Long Gene Fragments Up to 5.0Kb

Third quarter 2024 earnings released: US$1.47 loss per share (vs US$1.01 loss in 3Q 2023)

Twist Bioscience Corporation Updates Earnings Guidance for the Fourth Quarter and Full Year 2024

Twist Bioscience Corporation Announces Clinical Progression of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries

Twist Bioscience Corporation to Report Q3, 2024 Results on Aug 02, 2024

Twist Bioscience Corporation Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies

Twist Bioscience Corporation Launches Synthetic RNA Control for H5N1 Influenza A

Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor

Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-Throughput Screening Applications

New major risk - Share price stability

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.79 loss per share (vs US$1.04 loss in 2Q 2023)

Twist Bioscience Corporation Revises Earnings Guidance for the Fiscal Year 2024

Twist Bioscience Corporation to Report Q2, 2024 Results on May 02, 2024

Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Twist Bioscience Corporation Launches IVDR-Compliant Precision Dx Products for Whole Exome Sequencing

Twist Bioscience Corporation Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

Twist Bioscience Corporation Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

First quarter 2024 earnings released: US$0.75 loss per share (vs US$0.74 loss in 1Q 2023)

Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024

Twist Bioscience Corporation Expands Express Genes Rapid Synthesis Service

Twist Bioscience Corporation to Report Q1, 2024 Results on Feb 02, 2024

New minor risk - Shareholder dilution

Twist Bioscience Corporation, Annual General Meeting, Feb 06, 2024

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.60 loss per share (vs US$4.04 loss in FY 2022)

Twist Bioscience Corporation Provides Revenue Guidance for the First Quarter, Fourth Quarter and Full Fiscal Year of 2024

Twist Bioscience Corporation Launches Express Genes Rapid Gene Synthesis Service

Twist Bioscience Corporation to Report Q4, 2023 Results on Nov 17, 2023

Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable Pcr-Free Whole Genome Sequencing

Twist Bioscience Corporation Appoints Mark Buck as Senior Vice President, Operations

Third quarter 2023 earnings released: US$1.01 loss per share (vs US$1.08 loss in 3Q 2022)

Twist Bioscience Corporation to Report Q3, 2023 Results on Aug 04, 2023

Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism

Twist Bioscience Appoints Chet Gandhi as Chief Information Officer

Twist Bioscience Corporation Announces the Appointment of Robert Werner as Chief Accounting Officer

Senior VP recently bought €120k worth of stock

Second quarter 2023 earnings released: US$1.04 loss per share (vs US$1.14 loss in 2Q 2022)

Twist Bioscience Corporation Revises Financial Guidance for the Full Year 2023

Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform

The Portnoy Law Firm Announces Lawsuit Against Twist Bioscience Corporation

Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution

First quarter 2023 earnings released: US$0.74 loss per share (vs US$0.91 loss in 1Q 2022)

Twist Bioscience Corporation Provides Earnings Guidance for Second Quarter of 2023 and Fiscal Year 2024

Insufficient new directors

Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future

Twist Bioscience Corporation to Report Q1, 2023 Results on Feb 03, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Twist Bioscience Corporation, Annual General Meeting, Feb 07, 2023

Kessler Topaz Meltzer & Check, LLP Files a Securities Class Action Lawsuit Against Twist Bioscience Corporation

Full year 2022 earnings released: US$4.04 loss per share (vs US$3.15 loss in FY 2021)

Twist Bioscience Corporation Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2023 and 2024

Insufficient new directors

Twist Bioscience Corporation to Report Q4, 2022 Results on Nov 18, 2022

Twist Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Twist Bioscience Corporation Launches Human Sample ID Kit to Track Whole Blood Samples Through Lab Testing Workflow

Chief Financial Officer recently sold €247k worth of stock

Third quarter 2022 earnings released: US$1.08 loss per share (vs US$0.82 loss in 3Q 2021)

Twist Bioscience Corporation Provides Revenue Guidance for the Full Fiscal Year 2022

Twist Bioscience Corporation and Biotia, Inc. Receives Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2

Twist Bioscience Corporation to Report Q3, 2022 Results on Aug 05, 2022